Billionaires Buy Merck Site to Build Swiss Biotech Campus | Science | AAAS
Les 500 plus grandes fortunes de France en 2022 - Challenges
Jean-Paul Clozel | EY - Global
Jean-Paul Clozel et Martine Clozel - Les 500 plus grandes fortunes de France - Challenges
CEO Daily: Thursday, 26th January | Fortune
J&J snaps up Idorsia's resistant hypertension candidate, paying $230M | Fierce Biotech
Les secrets de management de Jean-Paul Clozel, l'homme qui a vendu sa biotech 30 milliards - Challenges
Jean-Paul Clozel
Deux stars de la biotech suisse réussissent une brillante entrée en bourse | 24 heures
Profile: Jean-Paul Clozel | Nature Biotechnology
Les 500 plus grandes fortunes de France en 2022 - Challenges
Johnson & Johnson Reportedly Aiming to Buy $17 Billion Biotech Firm | Fortune
Jean-Paul Clozel - CEO @ Idorsia - Crunchbase Person Profile
PharmaBoardroom - Jean-Paul Clozel - CEO & Co-Founder, Actelion, Switzerland
Idorsia will take three to four years to reach profitability, CEO says
5 éditeurs parmi les 500 plus grandes fortunes de France - Livres Hebdo
New Suitor Reportedly Replaced J&J in This $20 Billion Biotech Deal | Fortune
Novo Nordisk CEO Lars Sorensen Named World's 'Best-Performing CEO' | Fortune
Johnson & Johnson's $30 Billion Actelion Deal Is Finally Happening | Fortune
Actelion CEO Becomes a Billionaire With J&J's Bid for Drugmaker - Bloomberg
Speakers – Swiss HLG Winter Conference 2018 | by organizers.ch
Novo Nordisk CEO Lars Sorensen Named World's 'Best-Performing CEO' | Fortune
La Suisse a vu, en 2017, plus de milliardaires partir qu'arriver - SWI swissinfo.ch
Jean-Paul Clozel - CEO @ Idorsia - Crunchbase Person Profile
Actelion's Jean-Paul Clozel aims to keep group's independence | Financial Times
Who wants to be a billionaire? Not Actelion's founder and CEO, if it means selling out | Fierce Pharma
